1
|
Anand AK, Agarwal JP, D'Cruz A, Dattatreya PS, Goswami C, Joshi A, Julka PK, Noronha V, Prabhash K, Rao RR, Kumar R, Toprani R, Saxena V. Evolving multidisciplinary treatment of squamous cell carcinoma of the head and neck in India ✰. Cancer Treat Res Commun 2020; 26:100269. [PMID: 33338859 DOI: 10.1016/j.ctarc.2020.100269] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2020] [Revised: 11/17/2020] [Accepted: 12/07/2020] [Indexed: 06/12/2023]
Abstract
In this article, we highlight the evolution of a multimodal approach in the overall management of squamous cell carcinoma of the head and neck (SCCHN) in India; present advances in technology (newer surgical techniques), novel medical and radiotherapy (RT) approaches; review their roles for an integrated approach for treating SCCHN and discuss the current role of immunotherapy in SCCHN. For locally advanced (LA) SCCHN, the multidisciplinary approach includes surgery followed by RT, with or without chemotherapy (CT) or concurrent chemoradiotherapy. Improved surgical techniques of reconstruction and voice-preservation are being implemented. Advanced forms of high-precision conformal techniques like intensity-modulated radiotherapy are used to deliver highly conformal doses to tumors, sparing the surrounding normal tissue. Compared with RT alone, novel CT regimens and targeted therapeutic agents have the potential to improve locoregional control and survival and reduce treatment-induced toxicities. Several clinical trials have demonstrated efficacy, safety, and quality of life benefits of adding cetuximab to RT regimens in LASCCHN. Studies have also suggested a cetuximab-related laryngeal preservation benefit. At progression, platinum-based CT combined with cetuximab (a monoclonal anti-epidermal growth factor receptor antibody) is the only validated option available as the first-line therapy. Thus, an integrated multidisciplinary approach plays a key role in maximizing patient outcomes, reduction in treatment related morbidities that consequently impact quality of life of survivors.
Collapse
Affiliation(s)
- A K Anand
- Max Super Speciality Hospital, Delhi, India.
| | | | - A D'Cruz
- Tata Memorial Hospital, Mumbai, India
| | | | - C Goswami
- Superspeciality Hospital, Kolkata, India
| | - A Joshi
- Memorial Hospital, Mumbai, India
| | - P K Julka
- Max Super Speciality Hospital, Delhi, India.
| | - V Noronha
- Tata Memorial Hospital, Mumbai, India
| | | | | | | | - R Toprani
- Healthcare Global Enterprises Cancer Centre, Ahmedabad, India
| | - V Saxena
- Medical Affairs, Merck Specialities Pvt Ltd, India.
| |
Collapse
|
2
|
Li Y, Huang K, Fan H, Wu Z, Lu L, Chen M, Li F, Su J, Zhang M, Zhao S. Photodynamic therapy combined with simple surgery is effective as the palliative care for a patient with multiple squamous cell carcinomas. PHOTODERMATOLOGY PHOTOIMMUNOLOGY & PHOTOMEDICINE 2020; 37:85-87. [PMID: 32810336 DOI: 10.1111/phpp.12602] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/06/2020] [Revised: 07/14/2020] [Accepted: 08/15/2020] [Indexed: 11/27/2022]
Affiliation(s)
- Yixin Li
- Hunan Key Laboratory of Skin Cancer and Psoriasis, Hunan, China.,Xiangya School of Medicine, Central South University, Hunan, China
| | - Kai Huang
- Hunan Key Laboratory of Skin Cancer and Psoriasis, Hunan, China.,Hunan Engineering Research Center of Skin Health and Disease, Hunan, China.,Dermatology Department of Xiangya Hospital, Central South University, Hunan, China
| | - Hui Fan
- Hunan Key Laboratory of Skin Cancer and Psoriasis, Hunan, China.,Xiangya School of Medicine, Central South University, Hunan, China
| | - Zhijing Wu
- Hunan Key Laboratory of Skin Cancer and Psoriasis, Hunan, China.,Xiangya School of Medicine, Central South University, Hunan, China
| | - Lixia Lu
- Hunan Key Laboratory of Skin Cancer and Psoriasis, Hunan, China.,Hunan Engineering Research Center of Skin Health and Disease, Hunan, China.,Dermatology Department of Xiangya Hospital, Central South University, Hunan, China
| | - Mingliang Chen
- Hunan Key Laboratory of Skin Cancer and Psoriasis, Hunan, China.,Hunan Engineering Research Center of Skin Health and Disease, Hunan, China.,Dermatology Department of Xiangya Hospital, Central South University, Hunan, China
| | - Fangfang Li
- Hunan Key Laboratory of Skin Cancer and Psoriasis, Hunan, China.,Hunan Engineering Research Center of Skin Health and Disease, Hunan, China.,Dermatology Department of Xiangya Hospital, Central South University, Hunan, China
| | - Juan Su
- Hunan Key Laboratory of Skin Cancer and Psoriasis, Hunan, China.,Hunan Engineering Research Center of Skin Health and Disease, Hunan, China.,Dermatology Department of Xiangya Hospital, Central South University, Hunan, China
| | - Mi Zhang
- Hunan Key Laboratory of Skin Cancer and Psoriasis, Hunan, China.,Hunan Engineering Research Center of Skin Health and Disease, Hunan, China.,Dermatology Department of Xiangya Hospital, Central South University, Hunan, China
| | - Shuang Zhao
- Hunan Key Laboratory of Skin Cancer and Psoriasis, Hunan, China.,Hunan Engineering Research Center of Skin Health and Disease, Hunan, China.,Dermatology Department of Xiangya Hospital, Central South University, Hunan, China
| |
Collapse
|